Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04857151 · ClinicalTrials.gov registry record · Early Phase 1

Stress, Inflammation and Immune Response Pilot Study- Aim 3

A Early Phase 1 study, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Early Phase 1
Development phase
3
Enrollment target

NCT04857151 is a Early Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04857151, a Early Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Early Phase 1
Development phase
3 participants
Enrollment target

Study Summary

The overall goal of this study is to investigate the effects of stress and glucose intake at the molecular level including gene expression, protein and functional analysis of immune cells in real time. Aim 1- Characterizing the immune response after acute stress and glucose consumption Aim 2- Temporal mapping of the modulation of immune cell function via meditation Aim 3-Influence of meditative practice on lupus patients Aim 4-Influence of meditative practice on healthy subjects Current Clinicaltrials.gov record, will be focused on Aim-3 only. Aim-3 will test whether meditation alters neutrophil function and inflammation in patients with lupus. Study team will investigate whether patient neutrophils have altered NET formation, phagocytosis, ROS signaling and migration after ABMP. Innate immune function via analysis of monocytes by flow cytometry will also be analyzed. Other immune cell responses including CD8 T cells will also be investigated.

Interventions

  • BEHAVIORAL App based mindfulness program (ABMP)

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2022-02-02
Est. Completion 2024-03-31
Phase Early Phase 1

Sponsor

University of Wisconsin, Madison

1,039 total trials

What the Registry Record Tells You About NCT04857151

The ClinicalTrials.gov registry entry for NCT04857151 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which App based mindfulness program (ABMP) is the first listed.

NCT04857151 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04857151 about?

NCT04857151 is a clinical study titled "Stress, Inflammation and Immune Response Pilot Study- Aim 3". The overall goal of this study is to investigate the effects of stress and glucose intake at the molecular level including gene expression, protein and functional analysis of immune cells in real time. Aim 1- Characterizing the immune response after acute stress and glucose consumption Aim 2- Tempo...

What is the current status of trial NCT04857151?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2022-02-02. Estimated completion is 2024-03-31.

What interventions are being tested in trial NCT04857151?

The interventions under investigation include: App based mindfulness program (ABMP) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04857151?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.